The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.

CD44 forms a group of transmembranous glycoproteins formed by alternative splicing of a single mRNA. The expression of v6 exon-containing variants correlates with metastasis and poor prognosis in a number of malignancies. The distribution and prognostic value of CD44s, CD44v5, and CD44v6 were studied immunohistochemically in the radical prostatectomy specimens of 97 patients with prostate cancer and in 12 lymph node metastases. The mean follow-up period was 84 months. The percentage of CD44-immunoreactive cells was scored semiquantitatively. CD44 mRNA expression was studied in nine prostate cancer and eight benign prostatic hyperplasia (BPH) samples by reverse transcriptase-PCR. Benign prostatic glands almost always expressed CD44s, CD44v6, and, at a lower intensity, CD44v5. CD44 scores decreased from low- to high-grade prostatic intraepithelial neoplasia. CD44s, CD44v5, and CD44v6 were expressed in 86, 23, and 69% of the adenocarcinomas, respectively. Gleason sum score (GSS) and pT stage were correlated inversely with CD44s and CD44v6 scores. CD44 was not found in the lymph node metastatic tumor cells. At the mRNA level, 89% of the tumors and all BPH samples expressed CD44s. CD44v6-v10 mRNA was present in 44 and 75% of the tumors and BPH samples, respectively. Loss of CD44s and CD44v6 predicted an adverse prognosis at univariate analysis. The independent prognosticators identified by multivariate analysis were: GSS, pT stage, and CD44s for clinical progression; GSS and CD44s for prostate-specific antigen progression; and GSS for tumor-specific survival. Loss of CD44s expression in prostate adenocarcinoma predicts a poor prognosis, independent of stage and grade.

[1]  C. Corless.  Evaluating early-stage prostate cancer. What pretreatment criteria best guide therapeutic decision making? , 1996, Hematology/oncology clinics of North America.

[2]  R. Ho,et al.  The National Cancer Data Base report on longitudinal observations on prostate cancer , 1996, Cancer.

[3]  H. Moch,et al.  Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.

[4]  R. Midura,et al.  Expression of CD44 isoforms in human prostate tumor cell lines , 1996, The Prostate.

[5]  K. Friedrichs,et al.  CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. , 1995, Cancer research.

[6]  C G Chute,et al.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. , 1995, JAMA.

[7]  L. Bourguignon,et al.  Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells , 1995, Journal of cellular physiology.

[8]  J. Niloff,et al.  CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Eisterer,et al.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. , 1995, Blood.

[10]  P. Herrlich,et al.  CD44 variant exon epitopes in primary breast cancer and length of survival , 1995, The Lancet.

[11]  P. Schlag,et al.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins , 1995, The Lancet.

[12]  N. Block,et al.  Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. , 1995, Anticancer research.

[13]  D. Frappaz,et al.  Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. , 1995, European journal of cancer.

[14]  J. Oosting,et al.  Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins , 1994, The Lancet.

[15]  K. Washington,et al.  Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. , 1994, Human pathology.

[16]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[17]  W. Isaacs,et al.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.

[18]  Alvin Y. Liu.  Expression of CD44 in prostate cancer cells. , 1994, Cancer letters.

[19]  C. Mackay,et al.  Expression and modulation of CD44 variant isoforms in humans , 1994, The Journal of cell biology.

[20]  A. Verbeek,et al.  Mortality trend from prostate cancer in the Netherlands (1950‐1989) , 1994, The Prostate.

[21]  P. Troncoso,et al.  Biomarkers associated with prostate cancer progression. , 1994, Journal of cellular biochemistry. Supplement.

[22]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[23]  S Toikkanen,et al.  Glycoprotein CD44 expression and its association with survival in breast cancer. , 1993, The American journal of pathology.

[24]  S. Jalkanen,et al.  Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin , 1993, The Journal of cell biology.

[25]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[26]  D. Tarin,et al.  Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy , 1993, Journal of cellular biochemistry. Supplement.

[27]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Tarin,et al.  Significance of CD44 gene products for cancer diagnosis and disease evaluation , 1992, The Lancet.

[29]  Joe C. Adams,et al.  Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  F. Schröder,et al.  The TNM classification of prostate cancer , 1992, The Prostate. Supplement.

[31]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[33]  D. Jenkins,et al.  3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. , 1987, Journal of clinical pathology.

[34]  D. Bostwick,et al.  Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer , 1987, Cancer.

[35]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[36]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.